Portal de Periódicos da CAPES

A Crimean-Congo hemorrhagic fever (CCHF) viral vaccine expressing nucleoprotein is immunogenic but fails to confer protection against lethal disease

2015; Taylor & Francis; Volume: 12; Issue: 2 Linguagem: Inglês

10.1080/21645515.2015.1078045

2164-554X

Stuart Dowall, Karen R. Buttigieg, Stephen Findlay‐Wilson, Emma Rayner, Geoff Pearson, Miloszewska Aleksandra, Victoria Graham, Miles W. Carroll, Roger Hewson,

Viral Infections and Outbreaks Research

Crimean-Congo Hemorrhagic Fever (CCHF) is a severe tick-borne disease, endemic in many countries in Africa, the Middle East, Eastern Europe and Asia. Between 15-70% of reported cases are fatal with no approved vaccine available. In the present study, the attenuated poxvirus vector, Modified Vaccinia virus Ankara, was used to develop a recombinant candidate vaccine expressing the CCHF virus nucleoprotein. Cellular and humoral immunogenicity was confirmed in 2 mouse strains, including type I interferon receptor knockout mice, which are susceptible to CCHF disease. Despite the immune responses generated post-immunisation, the vaccine failed to protect animals from lethal disease in a challenge model.